Woman in science lab looking into microscope

Novozymes and Chr. Hansen to combine and create a leading global biosolutions partner



On December 12, 2022, Novozymes and Chr. Hansen announced that they have entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies.

On March 30, 2023, Novozymes’ and Chr. Hansen’s shareholders approved the combination to create a leading global biosolutions partner. The completion of the proposed merger is subject to customary merger control and other regulatory approvals from relevant authorities.

Please see below for documents and other relevant information regarding the proposed merger.

 


Key documents



ANNOUNCEMENTS

Investor news: Chinese merger approval granted, supporting the path to completion Investor news: Novozymes’ and Chr. Hansen’s shareholders approve combination to create a leading global biosolutions partner Investor news: Combination between Novozymes and Chr. Hansen approved by Novozymes’ shareholders Investor news on U.S. antitrust regulation Investor news on tax-exempt merger ruling Company announcement regarding proposed merger Press release regarding proposed merger
 

PRESENTATIONS

Investor presentation Conference call
 

MERGER DOCUMENTS

Merger plan Merger statement Fairness opinion by financial advisor Auditor valuation expert statement on the contemplated merger Auditor creditor statement
 

EXEMPTION DOCUMENT AND RELATED DOCUMENTS

Exemption document Retail brochure FAQ Memorandum of Association dated October 1, 2004 Articles of Association dated November 23, 2022 Remuneration report 2021/22
 

EXTRAORDINARY GENERAL MEETING MARCH 30, 2023

Minutes Presentation Votes cast Resolutions passed Notice to convene Registration form Draft amended articles of association Number of shares and votes Processing of personal data in connection with the EGM Proxy/postal vote form Watch the EGM webcast
 

EKSTRAORDINÆR GENERALFORSAMLING 30. MARTS 2023

Referat Beslutninger truffet Indkaldelse til ekstraordinær generalforsamling Forslag til ændrede vedtægter Antal aktier og stemmer Behandling af persondata Fuldmagt/brevstemmeblanket Tilmeldingsblanket Se liveudsendelsen af vores ekstraordinære generalforsamling
 

CHR. HANSEN ANNUAL REPORTS

Chr. Hansen Annual report 2021/22 Chr. Hansen Annual report 2020/21 Chr. Hansen Annual report 2019/20
 

NOVOZYMES ANNUAL REPORTS

Novozymes annual report 2022 Novozymes annual report 2021 Novozymes annual report 2020 Novozymes annual report 2019
 


Contacts


Investor relations 

Anders Mohr Christensen

Head of Investor Relations & Strategy

+45 2515 2364
dkamc@chr-hansen.com


Press relations

Sanne Seyer-Hansen

Head of Corporate Communications

+45 6038 6207
dksash@chr-hansen.com 



Restricted access


Access to this Website and the information contained herein is limited to persons resident:

  • in Denmark; OR
  • in the United States who are "qualified institutional buyers" as defined in Rule 144A under the U.S. Securities Act of 1933, as amended ("Securities Act") pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and who have executed an investor letter; OR
  • outside Denmark, the United States, Australia, Canada, South Africa, Japan and any jurisdiction in which it would be unlawful to access any prospectus, exemption document or other offer materials published by Chr. Hansen in connection with the proposed transaction.